By scRNA-seq on serial MPN and sAML patients, increased DUSP6 expression along disease progression from MPN to sAML was found, which mediated JAK2 resistance by activating RSK1 and then S6 phosphorylation. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.